519 related articles for article (PubMed ID: 19671845)
1. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.
Adam L; Zhong M; Choi W; Qi W; Nicoloso M; Arora A; Calin G; Wang H; Siefker-Radtke A; McConkey D; Bar-Eli M; Dinney C
Clin Cancer Res; 2009 Aug; 15(16):5060-72. PubMed ID: 19671845
[TBL] [Abstract][Full Text] [Related]
2. miR-200c inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3.
Liu L; Qiu M; Tan G; Liang Z; Qin Y; Chen L; Chen H; Liu J
J Transl Med; 2014 Nov; 12():305. PubMed ID: 25367080
[TBL] [Abstract][Full Text] [Related]
3. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
4. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
[TBL] [Abstract][Full Text] [Related]
5. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
6. miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers.
Vetter G; Saumet A; Moes M; Vallar L; Le Béchec A; Laurini C; Sabbah M; Arar K; Theillet C; Lecellier CH; Friederich E
Oncogene; 2010 Aug; 29(31):4436-48. PubMed ID: 20543867
[TBL] [Abstract][Full Text] [Related]
7. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
8. The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205.
Tran MN; Choi W; Wszolek MF; Navai N; Lee IL; Nitti G; Wen S; Flores ER; Siefker-Radtke A; Czerniak B; Dinney C; Barton M; McConkey DJ
J Biol Chem; 2013 Feb; 288(5):3275-88. PubMed ID: 23239884
[TBL] [Abstract][Full Text] [Related]
9. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.
McConkey DJ; Choi W; Marquis L; Martin F; Williams MB; Shah J; Svatek R; Das A; Adam L; Kamat A; Siefker-Radtke A; Dinney C
Cancer Metastasis Rev; 2009 Dec; 28(3-4):335-44. PubMed ID: 20012924
[TBL] [Abstract][Full Text] [Related]
10. Targets of miR-200c mediate suppression of cell motility and anoikis resistance.
Howe EN; Cochrane DR; Richer JK
Breast Cancer Res; 2011 Apr; 13(2):R45. PubMed ID: 21501518
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-124-3p suppresses cell migration and invasion by targeting ITGA3 signaling in bladder cancer.
Wang JR; Liu B; Zhou L; Huang YX
Cancer Biomark; 2019; 24(2):159-172. PubMed ID: 30614803
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24.
Cao Y; Yu SL; Wang Y; Guo GY; Ding Q; An RH
Tumour Biol; 2011 Feb; 32(1):179-88. PubMed ID: 20857258
[TBL] [Abstract][Full Text] [Related]
13. miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.
Mutlu M; Raza U; Saatci Ö; Eyüpoğlu E; Yurdusev E; Şahin Ö
J Mol Med (Berl); 2016 Jun; 94(6):629-44. PubMed ID: 27094812
[TBL] [Abstract][Full Text] [Related]
14. MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer.
Wu CL; Ho JY; Chou SC; Yu DS
Oncotarget; 2016 May; 7(18):26593-603. PubMed ID: 27058893
[TBL] [Abstract][Full Text] [Related]
15. The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells.
Zhang Z; Liu ZB; Ren WM; Ye XG; Zhang YY
Int J Mol Med; 2012 Oct; 30(4):856-62. PubMed ID: 22797360
[TBL] [Abstract][Full Text] [Related]
16. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro.
Dyrskjøt L; Ostenfeld MS; Bramsen JB; Silahtaroglu AN; Lamy P; Ramanathan R; Fristrup N; Jensen JL; Andersen CL; Zieger K; Kauppinen S; Ulhøi BP; Kjems J; Borre M; Orntoft TF
Cancer Res; 2009 Jun; 69(11):4851-60. PubMed ID: 19487295
[TBL] [Abstract][Full Text] [Related]
17. MiR-200 Regulates Epithelial-Mesenchymal Transition in Anaplastic Thyroid Cancer via EGF/EGFR Signaling.
Xue L; Su D; Li D; Gao W; Yuan R; Pang W
Cell Biochem Biophys; 2015 May; 72(1):185-90. PubMed ID: 25542369
[TBL] [Abstract][Full Text] [Related]
18. MiR-33a Controls hMSCS Osteoblast Commitment Modulating the Yap/Taz Expression Through EGFR Signaling Regulation.
Costa V; Carina V; Raimondi L; De Luca A; Bellavia D; Conigliaro A; Salamanna F; Alessandro R; Fini M; Giavaresi G
Cells; 2019 Nov; 8(12):. PubMed ID: 31771093
[TBL] [Abstract][Full Text] [Related]
19. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
20. Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.
Sato H; Shien K; Tomida S; Okayasu K; Suzawa K; Hashida S; Torigoe H; Watanabe M; Yamamoto H; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
Sci Rep; 2017 Jan; 7():40847. PubMed ID: 28084458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
